{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:02:36Z","timestamp":1787068956685,"version":"build-2736575974"},"reference-count":142,"publisher":"Rockefeller University Press","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012007","name":"Rockefeller University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012007","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002350","name":"St. Giles Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004343","name":"Stavros Niarchos Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI163029"],"award-info":[{"award-number":["R01AI163029"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001866"],"award-info":[{"award-number":["UL1TR001866"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001621","name":"Fisher Center for Alzheimer\u2019s Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005162","name":"Meyer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007457","name":"JPB Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007457","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-IAHU-01"],"award-info":[{"award-number":["ANR-10-IAHU-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-20-CE93-003"],"award-info":[{"award-number":["ANR-20-CE93-003"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-22-CE15-0046"],"award-info":[{"award-number":["ANR-22-CE15-0046"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-21-RHUS-08"],"award-info":[{"award-number":["ANR-21-RHUS-08"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-62-IBEID"],"award-info":[{"award-number":["ANR-10-LABX-62-IBEID"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"French Foundation for Medical Research","award":["EQU201903007798"],"award-info":[{"award-number":["EQU201903007798"]}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101057100"],"award-info":[{"award-number":["101057100"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","award":["GA 101191725"],"award-info":[{"award-number":["GA 101191725"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"crossref","award":["ANRS0629"],"award-info":[{"award-number":["ANRS0629"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"crossref","award":["ANRS-23-PEPR-MIE-0007"],"award-info":[{"award-number":["ANRS-23-PEPR-MIE-0007"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Square Foundation"},{"name":"Grandir - Fonds de solidarit\u00e9 pour l\u2019enfance"},{"DOI":"10.13039\/100012019","name":"Fondation du Souffle","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019631","name":"SCOR Corporate Foundation for Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019631","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Battersea & Bowery Advisory Group"},{"name":"General Atlantic Foundation"},{"DOI":"10.13039\/100012948","name":"Ministry of Higher Education, Research, and Innovation","doi-asserted-by":"publisher","award":["MESRI-COVID-19"],"award-info":[{"award-number":["MESRI-COVID-19"]}],"id":[{"id":"10.13039\/100012948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"name":"REACTing-INSERM"},{"name":"Paris Cit\u00e9 University"},{"DOI":"10.13039\/100017337","name":"Imagine Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","award":["RC08061819"],"award-info":[{"award-number":["RC08061819"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","award":["RC08061822"],"award-info":[{"award-number":["RC08061822"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"San Matteo Research Hospital","award":["08061821"],"award-info":[{"award-number":["08061821"]}]}],"content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,5]]},"abstract":"<jats:p>Human-tropic pathogenic arboviruses are spreading worldwide. There is immense interindividual clinical variability following infection with any arbovirus. Autoantibodies (auto-Abs) neutralizing antiviral type I IFNs (AAN-I-IFN) can underlie a small but growing number of severe arboviral diseases, whether transmitted by ticks (tick-borne encephalitis virus, TBEV; Powassan virus, POWV) or mosquitoes (West Nile virus, WNV; Usutu virus, USUV; Ross River virus, RRV) and whether due to flaviviruses (WNV, TBEV, POWV, and USUV) or alphaviruses (RRV). Evidence is documented in large cohort studies for WNV and TBEV. They can also account severe adverse reactions to the live-attenuated yellow fever virus vaccine. AAN-I-IFN are present before arboviral infection and are the cause of severe disease. Carriers of these auto-Abs are common worldwide (&amp;gt;100 million people), have a very high risk of severe disease (relative risk &amp;gt;100), and account for a sizeable proportion of cases (typically &amp;gt;10%). Other severe diseases due to different arboviruses may also be caused by these auto-Abs.<\/jats:p>","DOI":"10.70962\/jhi.20250090","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T06:21:24Z","timestamp":1759818084000},"update-policy":"https:\/\/doi.org\/10.70962\/jhi.crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Auto-Abs against type I IFNs: Strong, common, and global determinants of severe arboviral diseases"],"prefix":"10.70962","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1083-5787","authenticated-orcid":true,"given":"Adrian","family":"Gervais","sequence":"first","affiliation":[{"name":"Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U1163, Necker Hospital for Sick Children 1 , Paris,","place":["France"]},{"id":[{"id":"https:\/\/ror.org\/05f82e368","id-type":"ROR","asserted-by":"publisher"}],"name":"Paris Cit\u00e9 University, Imagine Institute 2 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8773-9144","authenticated-orcid":true,"given":"Alessandro","family":"Borghesi","sequence":"additional","affiliation":[{"name":"Host-Pathogen Group, San Matteo Research Hospital 3 , Pavia,","place":["Italy"]},{"name":"Neonatal Intensive Care Unit, San Matteo Research Hospital 4 , Pavia,","place":["Italy"]},{"name":"Neonatal Intensive Care Unit, Geneva University Hospitals 5 Mother, Child and Adolescent Department, , Geneva,","place":["Switzerland"]},{"name":"Faculty of Medicine, University of Geneva 6 Department of Pediatrics, Gynecology and Obstetrics, , Geneva,","place":["Switzerland"]},{"name":"School of Life Sciences, Swiss Federal Institute of Technology 7 , Lausanne,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7782-4169","authenticated-orcid":true,"given":"Jean-Laurent","family":"Casanova","sequence":"additional","affiliation":[{"name":"Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U1163, Necker Hospital for Sick Children 1 , Paris,","place":["France"]},{"id":[{"id":"https:\/\/ror.org\/05f82e368","id-type":"ROR","asserted-by":"publisher"}],"name":"Paris Cit\u00e9 University, Imagine Institute 2 , Paris,","place":["France"]},{"id":[{"id":"https:\/\/ror.org\/0420db125","id-type":"ROR","asserted-by":"publisher"}],"name":"St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University 8 , New York, NY,","place":["USA"]},{"name":"Howard Hughes Medical Institute 9 , New York, NY,","place":["USA"]},{"name":"Necker Hospital for Sick Children, Assistance Publique \u2013 H\u00f4pitaux de Paris 10 Department of Pediatrics, , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9449-3672","authenticated-orcid":true,"given":"Shen-Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U1163, Necker Hospital for Sick Children 1 , Paris,","place":["France"]},{"id":[{"id":"https:\/\/ror.org\/05f82e368","id-type":"ROR","asserted-by":"publisher"}],"name":"Paris Cit\u00e9 University, Imagine Institute 2 , Paris,","place":["France"]},{"id":[{"id":"https:\/\/ror.org\/0420db125","id-type":"ROR","asserted-by":"publisher"}],"name":"St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University 8 , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"2025102309245236500_bib1","volume-title":"Reference Module in Biomedical Sciences","author":"Artsob","year":"2023"},{"key":"2025102309245236500_bib2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.vetmic.2009.08.024","article-title":"Zoonotic tick-borne flaviviruses","volume":"140","author":"Dobler","year":"2010","journal-title":"Vet. Microbiol."},{"key":"2025102309245236500_bib3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.14423\/SMJ.0000000000001152","article-title":"Arboviruses and their vectors","volume":"113","author":"Madewell","year":"2020","journal-title":"South. Med. J."},{"key":"2025102309245236500_bib4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.actatropica.2016.11.020","article-title":"The emergence of arthropod-borne viral diseases: A global prospective on dengue, chikungunya and zika fevers","volume":"166","author":"Mayer","year":"2017","journal-title":"Acta Trop."},{"key":"2025102309245236500_bib5","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s00705-023-05835-1","article-title":"Renaming of the genus Flavivirus to Orthoflavivirus and extension of binomial species names within the family Flaviviridae","volume":"168","author":"Postler","year":"2023","journal-title":"Arch. Virol."},{"key":"2025102309245236500_bib6","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.tim.2022.07.002","article-title":"Disease-causing human viruses: Novelty and legacy","volume":"30","author":"Forni","year":"2022","journal-title":"Trends Microbiol."},{"key":"2025102309245236500_bib7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-micro-092123-022855","article-title":"The microbe, the infection enigma, and the host","volume":"78","author":"Casanova","year":"2024","journal-title":"Annu. Rev. Microbiol."},{"key":"2025102309245236500_bib8","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1038\/s41467-024-47161-3","article-title":"Challenges in combating arboviral infections","volume":"15","author":"Troppens","year":"2024","journal-title":"Nat. Commun."},{"key":"2025102309245236500_bib9","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1016\/S1473-3099(16)30518-7","article-title":"Epidemic arboviral diseases: Priorities for research and public health","volume":"17","author":"Wilder-Smith","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"2025102309245236500_bib10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.antiviral.2009.10.008","article-title":"Present and future arboviral threats","volume":"85","author":"Weaver","year":"2010","journal-title":"Antivir. Res."},{"key":"2025102309245236500_bib11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/v17030439","article-title":"A comprehensive review of the neglected and emerging Oropouche virus","volume":"17","author":"Bai","year":"2025","journal-title":"Viruses"},{"key":"2025102309245236500_bib12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3390\/v17030353","article-title":"Oropouche virus (OROV): Expanding threats, shifting patterns, and the urgent need for collaborative research in Latin America","volume":"17","author":"Ribas Freitas","year":"2025","journal-title":"Viruses"},{"key":"2025102309245236500_bib13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ana.27139","article-title":"Oropouche virus: An emerging neuroinvasive arbovirus","volume":"97","author":"Pastula","year":"2024","journal-title":"Ann. Neurol."},{"key":"2025102309245236500_bib14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.7861\/clinmedicine.19-2-149","article-title":"Global warming and arboviral infections","volume":"19","author":"Whitehorn","year":"2019","journal-title":"Clin. Med."},{"key":"2025102309245236500_bib15","doi-asserted-by":"publisher","first-page":"101532","DOI":"10.1016\/j.nmni.2024.101532","article-title":"Climate change and arboviruses_a growing threat to public health","volume":"62","author":"Mousavi","year":"2024","journal-title":"New Microbes New Infect."},{"key":"2025102309245236500_bib16","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/s12879-025-10824-7","article-title":"Epidemiology of arboviruses in humans and livestock in Ethiopia: A systematic review and meta-analysis","volume":"25","author":"Gedefie","year":"2025","journal-title":"BMC Infect. Dis."},{"key":"2025102309245236500_bib17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1478-7954-9-1","article-title":"Measuring the burden of arboviral diseases: The spectrum of morbidity and mortality from four prevalent infections","volume":"9","author":"Labeaud","year":"2011","journal-title":"Popul. Health Metr."},{"key":"2025102309245236500_bib18","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1056\/NEJMra030476","article-title":"Flavivirus encephalitis","volume":"351","author":"Solomon","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"2025102309245236500_bib19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198357","article-title":"Risk factors for arbovirus infections in a low-income community of Rio de Janeiro, Brazil, 2015\u20132016","volume":"13","author":"Rodrigues","year":"2018","journal-title":"PLoS One"},{"key":"2025102309245236500_bib20","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s11481-010-9234-7","article-title":"Arboviral encephalitides: Transmission, emergence, and pathogenesis","volume":"5","author":"Hollidge","year":"2010","journal-title":"J. Neuroimmune Pharmacol."},{"key":"2025102309245236500_bib21","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/cid\/ciz635","article-title":"Clinical epidemiology, risk factors, and outcomes of encephalitis in older adults","volume":"70","author":"Hansen","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"2025102309245236500_bib22","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.immuni.2024.05.020","article-title":"Human determinants of age-dependent patterns of death from infection","volume":"57","author":"Abel","year":"2024","journal-title":"Immunity"},{"key":"2025102309245236500_bib23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature09907","article-title":"A diverse range of gene products are effectors of the type I interferon antiviral response","volume":"472","author":"Schoggins","year":"2011","journal-title":"Nature"},{"key":"2025102309245236500_bib24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrmicro2950","article-title":"West Nile virus infection and immunity","volume":"11","author":"Suthar","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"2025102309245236500_bib25","doi-asserted-by":"publisher","first-page":"13350","DOI":"10.1128\/jvi.79.21.13350-13361.2005","article-title":"Alpha\/Beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival","volume":"79","author":"Samuel","year":"2005","journal-title":"J. Virol."},{"key":"2025102309245236500_bib26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024745","article-title":"Host genetic risk factors for West Nile virus infection and disease progression","volume":"6","author":"Bigham","year":"2011","journal-title":"PLoS One"},{"key":"2025102309245236500_bib27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000345934","article-title":"Genetic susceptibility to West Nile virus and dengue","volume":"16","author":"Loeb","year":"2013","journal-title":"Public Health Genomics"},{"key":"2025102309245236500_bib28","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1017\/S0950268814001290","article-title":"Genetic variants associated with susceptibility of Ashkenazi Jews to West Nile virus infection","volume":"143","author":"Danial-Farran","year":"2015","journal-title":"Epidemiol. Infect."},{"key":"2025102309245236500_bib29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022948","article-title":"Association between HLA class I and class II alleles and the outcome of West Nile virus infection: An exploratory study","volume":"6","author":"Lanteri","year":"2011","journal-title":"PLoS One"},{"key":"2025102309245236500_bib30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1084\/jem.20051970","article-title":"CCR5 deficiency increases risk of symptomatic West Nile virus infection","volume":"203","author":"Glass","year":"2006","journal-title":"J. Exp. Med."},{"key":"2025102309245236500_bib31","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41586-022-04447-0","article-title":"Human genetic and immunological determinants of critical COVID-19 pneumonia","volume":"603","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"2025102309245236500_bib32","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"2025102309245236500_bib33","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl4340","article-title":"Autoantibodies neutralizing type I IFNs are present in \u223c4% of uninfected individuals over 70 years old and account for \u223c20% of COVID-19 deaths","volume":"6","author":"Bastard","year":"2021","journal-title":"Sci. Immunol."},{"key":"2025102309245236500_bib34","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/imcb.12495","article-title":"Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19","volume":"99","author":"Abers","year":"2021","journal-title":"Immunol. Cell Biol."},{"key":"2025102309245236500_bib35","doi-asserted-by":"publisher","first-page":"102598","DOI":"10.1016\/j.jaut.2021.102598","article-title":"COVID-19 convalescent plasma composition and immunological effects in severe patients","volume":"118","author":"Acosta-Ampudia","year":"2021","journal-title":"J. Autoimmun."},{"key":"2025102309245236500_bib36","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.1038\/s41467-021-25509-3","article-title":"New-onset IgG autoantibodies in hospitalized patients with COVID-19","volume":"12","author":"Chang","year":"2021","journal-title":"Nat. Commun."},{"key":"2025102309245236500_bib37","doi-asserted-by":"publisher","first-page":"rs.3.rs-915062","DOI":"10.21203\/rs.3.rs-915062\/v1","article-title":"Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital","volume":"43","author":"Chauvineau-Grenier","year":"2021","journal-title":"Res. Sq."},{"key":"2025102309245236500_bib38","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1327","article-title":"Antibodies against type I interferon: Detection and association with severe clinical outcome in COVID-19 patients","volume":"10","author":"Goncalves","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"2025102309245236500_bib39","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s00134-021-06392-4","article-title":"Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients","volume":"47","author":"Koning","year":"2021","journal-title":"Intensive Care Med."},{"key":"2025102309245236500_bib40","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jaci.2021.03.034","article-title":"Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis","volume":"148","author":"Lemarquis","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"2025102309245236500_bib41","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s10875-021-01136-x","article-title":"Pre-existing autoantibodies neutralizing high concentrations of type I interferons in almost 10% of COVID-19 patients admitted to intensive care in barcelona","volume":"41","author":"Solanich","year":"2021","journal-title":"J. Clin. Immunol."},{"key":"2025102309245236500_bib42","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s10875-021-01036-0","article-title":"Neutralizing autoantibodies to type I IFNs in &gt;10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain","volume":"41","author":"Troya","year":"2021","journal-title":"J. Clin. Immunol."},{"key":"2025102309245236500_bib43","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh2624","article-title":"Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19","volume":"13","author":"van der Wijst","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"2025102309245236500_bib44","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s10875-021-01060-0","article-title":"Neutralizing autoantibodies to type I interferons in COVID-19 convalescent donor plasma","volume":"41","author":"Vazquez","year":"2021","journal-title":"J. Clin. Immunol."},{"key":"2025102309245236500_bib45","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03631-y","article-title":"Diverse functional autoantibodies in patients with COVID-19","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"2025102309245236500_bib46","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1016\/j.cell.2021.07.023","article-title":"Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19","volume":"184","author":"Ziegler","year":"2021","journal-title":"Cell"},{"key":"2025102309245236500_bib47","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s10875-022-01252-2","article-title":"Early and rapid identification of COVID-19 patients with neutralizing type I interferon auto-antibodies","volume":"42","author":"Akbil","year":"2022","journal-title":"J. Clin. Immunol."},{"key":"2025102309245236500_bib48","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj7521","article-title":"Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort","volume":"14","author":"Carapito","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"2025102309245236500_bib49","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/eji.202249824","article-title":"Anti-IFN-\u03b1\/-\u03c9 neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity","volume":"52","author":"Frasca","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"2025102309245236500_bib50","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s10875-021-01168-3","article-title":"Interferon-\u03b12 auto-antibodies in convalescent plasma therapy for COVID-19","volume":"42","author":"Raadsen","year":"2022","journal-title":"J. Clin. Immunol."},{"key":"2025102309245236500_bib51","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01280-22","article-title":"Increased presence of antibodies against type I interferons and human endogenous retrovirus W in intensive care unit COVID-19 patients","volume":"10","author":"Simula","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"2025102309245236500_bib52","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12964-022-00903-6","article-title":"A comprehensive evaluation of the immune system response and type-I Interferon signaling pathway in hospitalized COVID-19 patients","volume":"20","author":"Soltani-Zangbar","year":"2022","journal-title":"Cell Commun. Signal."},{"key":"2025102309245236500_bib53","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150867","article-title":"Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1","volume":"131","author":"Meisel","year":"2021","journal-title":"J. Clin. Invest."},{"key":"2025102309245236500_bib54","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s10875-022-01325-2","article-title":"Clinical and immunological features of SARS-CoV-2 breakthrough infections in vaccinated individuals requiring hospitalization","volume":"42","author":"Lamacchia","year":"2022","journal-title":"J. Clin. Immunol."},{"key":"2025102309245236500_bib55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001709","article-title":"Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease","volume":"20","author":"Busnadiego","year":"2022","journal-title":"PLoS Biol."},{"key":"2025102309245236500_bib56","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1007\/s10875-022-01308-3","article-title":"Neutralizing type I interferon autoantibodies in Japanese patients with severe COVID-19","volume":"42","author":"Eto","year":"2022","journal-title":"J. Clin. Immunol."},{"key":"2025102309245236500_bib57","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.3390\/v13122553","article-title":"Microarray-based detection of antibodies against SARS-CoV-2 proteins, common respiratory viruses and type I interferons","volume":"13","author":"Savvateeva","year":"2021","journal-title":"Viruses"},{"key":"2025102309245236500_bib58","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/s41551-022-00925-y","article-title":"Unbiased discovery of autoantibodies associated with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries","volume":"6","author":"Credle","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"2025102309245236500_bib59","doi-asserted-by":"publisher","first-page":"279","DOI":"10.15789\/2220-7619-aaa-1789","article-title":"Anti-interferon alpha autoantibodies and their significance in COVID-19","volume":"12","author":"Petrikov","year":"2022","journal-title":"Russ. J. Infect. Immun."},{"key":"2025102309245236500_bib60","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10875-022-01245-1","article-title":"Diagnosis of APS-1 in two siblings following life-threatening COVID-19 pneumonia","volume":"42","author":"Schidlowski","year":"2022","journal-title":"J. Clin. Immunol."},{"key":"2025102309245236500_bib61","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13613-022-01095-5","article-title":"Auto-antibodies against type I IFNs in\u2009&gt;\u200910% of critically ill COVID-19 patients: A prospective multicentre study","volume":"12","author":"Arrestier","year":"2022","journal-title":"Ann. Intensive Care"},{"key":"2025102309245236500_bib62","doi-asserted-by":"publisher","first-page":"143","DOI":"10.20411\/pai.v7i2.537","article-title":"Immune dysregulation in acute SARS-CoV-2 infection","volume":"7","author":"Grimm","year":"2022","journal-title":"Pathog. Immun."},{"key":"2025102309245236500_bib63","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s10875-023-01512-9","article-title":"Autoantibodies neutralizing type I IFNs in the bronchoalveolar lavage of at least 10% of patients during life-threatening COVID-19 pneumonia","volume":"43","author":"Philippot","year":"2023","journal-title":"J. Clin. Immunol."},{"key":"2025102309245236500_bib64","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1089\/jir.2023.0003","article-title":"Autoantibodies neutralizing type III interferons are uncommon in patients with severe coronavirus disease 2019 pneumonia","volume":"43","author":"Vanker","year":"2023","journal-title":"J. Interferon Cytokine Res."},{"key":"2025102309245236500_bib65","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29089","article-title":"Examination of autoantibodies to type I interferon in patients suffering from long COVID","volume":"95","author":"Hansen","year":"2023","journal-title":"J. Med. Virol."},{"key":"2025102309245236500_bib66","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1136\/ard-2022-222549","article-title":"Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-\u03b1","volume":"81","author":"Mathian","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"2025102309245236500_bib67","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1089\/jir.2023.0087","article-title":"High anti-interferon-alpha autoantibody levels in severe\/critical COVID-19 patients from Peru","volume":"43","author":"Pons","year":"2023","journal-title":"J. Interferon Cytokine Res."},{"key":"2025102309245236500_bib68","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.cell.2022.01.014","article-title":"Multiple early factors anticipate post-acute COVID-19 sequelae","volume":"185","author":"Su","year":"2022","journal-title":"Cell"},{"key":"2025102309245236500_bib69","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"2025102309245236500_bib70","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3389\/fimmu.2018.02061","article-title":"The dual nature of type I and type II interferons","volume":"9","author":"Lee","year":"2018","journal-title":"Front. Immunol."},{"key":"2025102309245236500_bib71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2008.11.002","article-title":"Interferons: Signaling, antiviral and viral evasion","volume":"122","author":"Bonjardim","year":"2009","journal-title":"Immunol. Lett."},{"key":"2025102309245236500_bib72","doi-asserted-by":"publisher","DOI":"10.1101\/2024.02.27.24303363","article-title":"Longitudinal analysis over decades reveals the development and immune implications of type I interferon autoantibodies in an aging population","author":"Sonja","year":"2024","journal-title":"medRxiv"},{"key":"2025102309245236500_bib73","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220514","article-title":"Autoantibodies against type I IFNs in patients with critical influenza pneumonia","volume":"219","author":"Zhang","year":"2022","journal-title":"J. Exp. Med."},{"key":"2025102309245236500_bib74","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13116","article-title":"Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial","volume":"17","author":"Alotaibi","year":"2023","journal-title":"Influenza Other Respir. Viruses"},{"key":"2025102309245236500_bib75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2015.09.019","article-title":"Comparison of three neurotropic viruses reveals differences in viral dissemination to the central nervous system","volume":"487","author":"Luethy","year":"2016","journal-title":"Virology"},{"key":"2025102309245236500_bib76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010610","article-title":"Epidemiology of yellow fever virus in humans, arthropods, and non-human primates in sub-Saharan Africa: A systematic review and meta-analysis","volume":"16","author":"Oyono","year":"2022","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2025102309245236500_bib77","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/10408360490497474","article-title":"Yellow fever: The recurring plague","volume":"41","author":"Tomori","year":"2004","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"2025102309245236500_bib78","doi-asserted-by":"publisher","first-page":"126423","DOI":"10.1016\/j.vaccine.2024.126423","article-title":"Breakthroughs and insights: A comprehensive review of yellow fever vaccine breakthrough infection across 8 decades","volume":"43","author":"Coulter","year":"2025","journal-title":"Vaccine"},{"key":"2025102309245236500_bib79","doi-asserted-by":"publisher","first-page":"100937","DOI":"10.1016\/j.lanmic.2024.06.004","article-title":"Yellow fever breakthrough infections after yellow fever vaccination: A systematic review and meta-analysis","volume":"5","author":"Schnyder","year":"2024","journal-title":"Lancet Microbe"},{"key":"2025102309245236500_bib80","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41541-020-0205-6","article-title":"Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection","volume":"5","author":"Staples","year":"2020","journal-title":"Npj Vaccin."},{"key":"2025102309245236500_bib81","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(01)05341-7","article-title":"Hepatitis and death following vaccination with 17D-204 yellow fever vaccine","volume":"358","author":"Chan","year":"2001","journal-title":"Lancet"},{"key":"2025102309245236500_bib82","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0140-6736(01)05327-2","article-title":"Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: A report of four cases","volume":"358","author":"Martin","year":"2001","journal-title":"Lancet"},{"key":"2025102309245236500_bib83","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.1016\/j.vaccine.2014.08.051","article-title":"Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD)","volume":"32","author":"Seligman","year":"2014","journal-title":"Vaccine"},{"key":"2025102309245236500_bib84","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/14760584.2016.1180250","article-title":"Yellow fever vaccine: Worthy friend or stealthy foe?","volume":"15","author":"Seligman","year":"2016","journal-title":"Expert Rev. Vaccin."},{"key":"2025102309245236500_bib85","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0140-6736(01)05326-0","article-title":"Serious adverse events associated with yellow fever 17DD vaccine in Brazil: A report of two cases","volume":"358","author":"Vasconcelos","year":"2001","journal-title":"Lancet"},{"key":"2025102309245236500_bib86","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1084\/jem.20182295","article-title":"Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines","volume":"216","author":"Hernandez","year":"2019","journal-title":"J. Exp. Med."},{"key":"2025102309245236500_bib87","doi-asserted-by":"publisher","DOI":"10.1084\/JEM.20202486","article-title":"Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine","volume":"218","author":"Bastard","year":"2021","journal-title":"J. Exp. Med."},{"key":"2025102309245236500_bib88","doi-asserted-by":"publisher","first-page":"taad160","DOI":"10.1093\/jtm\/taad160","article-title":"Yellow fever vaccine-associated neurologic and viscerotropic disease: A 10-year case series of the French national reference center for arboviruses with clinical and immunological insights","volume":"31","author":"Le Hir","year":"2024","journal-title":"J. Trav. Med."},{"key":"2025102309245236500_bib89","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0140-6736(01)05480-0","article-title":"Epidemic West nile encephalitis, New York, 1999: Results of a household-based seroepidemiological survey","volume":"358","author":"Mostashari","year":"2001","journal-title":"Lancet"},{"key":"2025102309245236500_bib90","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3201\/eid1205.051287","article-title":"West nile virus infections projected from blood donor screening data, United States, 2003","volume":"12","author":"Busch","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"2025102309245236500_bib91","first-page":"1","article-title":"Surveillance for human West Nile virus disease - United States, 1999\u20132008","volume":"59","author":"Lindsey","year":"2010","journal-title":"MMWR Surveill. Summ."},{"key":"2025102309245236500_bib92","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3201\/eid1804.111313","article-title":"Neuroinvasive disease and West Nile virus infection, North Dakota, USA, 1999\u20132008","volume":"18","author":"Carson","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"2025102309245236500_bib93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080432","article-title":"Population seroprevalence study after a West Nile virus lineage 2 epidemic, Greece, 2010","volume":"8","author":"Ladbury","year":"2013","journal-title":"PLoS One"},{"key":"2025102309245236500_bib94","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4269\/ajtmh.2012.12-0113","article-title":"Medical risk factors for severe West Nile virus disease, United States, 2008\u20132010","volume":"87","author":"Lindsey","year":"2012","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"2025102309245236500_bib95","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41467-024-45290-3","article-title":"Contribution of climate change to the spatial expansion of West Nile virus in Europe","volume":"15","author":"Erazo","year":"2024","journal-title":"Nat. Commun."},{"key":"2025102309245236500_bib96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pclm.0000129","article-title":"West Nile virus eco-epidemiology and climate change","volume":"2","author":"Heidecke","year":"2023","journal-title":"PLoS Clim."},{"key":"2025102309245236500_bib97","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/vetsci12030288","article-title":"West nile virus (WNV): One-health and eco-health global risks","volume":"12","author":"Bruno","year":"2025","journal-title":"Vet. Sci."},{"key":"2025102309245236500_bib98","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1001\/jama.2025.8737","article-title":"West nile virus: A review","volume":"334","author":"Gould","year":"2025","journal-title":"JAMA"},{"key":"2025102309245236500_bib99","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230661","article-title":"Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in \u223c40% of patients","volume":"220","author":"Gervais","year":"2023","journal-title":"J. Exp. Med."},{"key":"2025102309245236500_bib100","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1093\/infdis\/jiae321","article-title":"Severe West Nile virus and severe acute respiratory syndrome coronavirus 2 infections in a patient with thymoma and anti\u2013type I interferon antibodies","volume":"231","author":"Barzaghi","year":"2025","journal-title":"J. Infect. Dis."},{"key":"2025102309245236500_bib101","doi-asserted-by":"publisher","first-page":"11271","DOI":"10.1038\/s41598-025-89312-6","article-title":"Human type I interferons protect Vero E6 and ARPE-19 cells against West Nile virus and are neutralized by pathogenic autoantibodies","volume":"15","author":"Ferrari","year":"2025","journal-title":"Sci. Rep."},{"key":"2025102309245236500_bib102","doi-asserted-by":"publisher","first-page":"5973","DOI":"10.1038\/s41467-023-41600-3","article-title":"Blockade of interferon signaling decreases gut barrier integrity and promotes severe West Nile virus disease","volume":"14","author":"Lin","year":"2023","journal-title":"Nat. Commun."},{"key":"2025102309245236500_bib103","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240942","article-title":"Auto-Abs neutralizing type I IFNs in patients with severe Powassan, Usutu, or Ross River virus disease","volume":"221","author":"Gervais","year":"2024","journal-title":"J. Exp. Med."},{"key":"2025102309245236500_bib104","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1086\/515195","article-title":"Tick-borne encephalitis","volume":"28","author":"Dumpis","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"2025102309245236500_bib105","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/BF01962369","article-title":"Two-year survey of the incidence of Lyme borreliosis and tick-borne encephalitis in a high-risk population in Sweden","volume":"11","author":"Gustafson","year":"1992","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"2025102309245236500_bib106","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.idc.2008.03.013","article-title":"Tick-borne encephalitis","volume":"22","author":"Kaiser","year":"2008","journal-title":"Infect. Dis. Clin. North Am."},{"key":"2025102309245236500_bib107","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.tmaid.2010.05.011","article-title":"What tick-borne encephalitis may look like: Clinical signs and symptoms","volume":"8","author":"Bogovic","year":"2010","journal-title":"Trav. Med. Infect. Dis."},{"key":"2025102309245236500_bib108","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240637","article-title":"Autoantibodies neutralizing type I IFNs underlie severe tick-borne encephalitis in \u223c10% of patients","volume":"221","author":"Gervais","year":"2024","journal-title":"J. Exp. Med."},{"key":"2025102309245236500_bib109","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3390\/cells10030708","article-title":"Aging and interferons: Impacts on inflammation and viral disease outcomes","volume":"10","author":"Feng","year":"2021","journal-title":"Cells"},{"key":"2025102309245236500_bib110","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-002113","article-title":"IFN production ability and healthy ageing: Mixed model analysis of a 24 year longitudinal study in Japan","volume":"3","author":"Uno","year":"2013","journal-title":"BMJ Open"},{"key":"2025102309245236500_bib111","doi-asserted-by":"publisher","first-page":"865","DOI":"10.4049\/jimmunol.1402389","article-title":"Age-associated failure to adjust type I IFN receptor signaling thresholds after T cell activation","volume":"195","author":"Li","year":"2015","journal-title":"J. Immunol."},{"key":"2025102309245236500_bib112","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13223-019-0321-x","article-title":"West Nile virus encephalitis in GATA2 deficiency","volume":"15","author":"Rosa","year":"2019","journal-title":"Allergy Asthma. Clin. Immunol."},{"key":"2025102309245236500_bib113","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"2025102309245236500_bib114","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1089\/vbz.2017.2110","article-title":"Powassan virus: An emerging arbovirus of public health concern in North America","volume":"17","author":"Hermance","year":"2017","journal-title":"Vector Borne Zoonotic Dis."},{"key":"2025102309245236500_bib115","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.idc.2022.03.003","article-title":"Powassan virus encephalitis","volume":"36","author":"Piantadosi","year":"2022","journal-title":"Infect. Dis. Clin. North Am."},{"key":"2025102309245236500_bib116","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/v7010219","article-title":"Usutu virus: An emerging flavivirus in Europe","volume":"7","author":"Ashraf","year":"2015","journal-title":"Viruses"},{"key":"2025102309245236500_bib117","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1089\/vbz.2011.0631","article-title":"Usutu virus in Africa","volume":"11","author":"Nikolay","year":"2011","journal-title":"Vector Borne Zoonotic Dis."},{"key":"2025102309245236500_bib118","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/v15010077","article-title":"Human Usutu virus infections in Europe: A new risk on Horizon?","volume":"15","author":"Cadar","year":"2022","journal-title":"Viruses"},{"key":"2025102309245236500_bib119","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s13365-023-01148-w","article-title":"Case report of Usutu virus infection in an immunocompromised patient in Italy, 2022","volume":"29","author":"Gaibani","year":"2023","journal-title":"J. Neurovirol."},{"key":"2025102309245236500_bib120","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268819001213","article-title":"Usutu virus: A new threat?","volume":"147","author":"Cl\u00e9","year":"2019","journal-title":"Epidemiol. Infect."},{"key":"2025102309245236500_bib121","doi-asserted-by":"publisher","first-page":"19935","DOI":"10.2807\/ese.16.31.19935-en","article-title":"USUTU virus \u2013 potential risk of human disease in Europe","volume":"16","author":"V\u00e1zquez Gonz\u00e1lez","year":"2011","journal-title":"Euro Surveill."},{"key":"2025102309245236500_bib122","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s13365-019-00818-y","article-title":"Usutu virus disease: A potential problem for North America?","volume":"26","author":"Gill","year":"2020","journal-title":"J. Neurovirol."},{"key":"2025102309245236500_bib123","doi-asserted-by":"publisher","first-page":"1115501","DOI":"10.3389\/fvets.2023.1115501","article-title":"Usutu virus: An emerging flavivirus with potential threat to public health in Africa: Nigeria as a case study","volume":"10","author":"Akinsulie","year":"2023","journal-title":"Front. Vet. Sci."},{"key":"2025102309245236500_bib124","doi-asserted-by":"publisher","first-page":"2200929","DOI":"10.2807\/1560-7917.ES.2023.28.33.2200929","article-title":"Epidemiology, surveillance and diagnosis of Usutu virus infection in the EU\/EEA, 2012 to 2021","volume":"28","author":"Angeloni","year":"2023","journal-title":"Euro. Surveill."},{"key":"2025102309245236500_bib125","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3390\/pathogens9090699","article-title":"Epidemiology of Usutu virus: The European scenario","volume":"9","author":"Vilibic-Cavlek","year":"2020","journal-title":"Pathogens"},{"key":"2025102309245236500_bib126","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.3390\/v16101606","article-title":"Epidemiology and ecology of Usutu virus infection and its global risk distribution","volume":"16","author":"Chen","year":"2024","journal-title":"Viruses"},{"key":"2025102309245236500_bib127","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1128\/cmr.14.4.909-932.2001","article-title":"Ross River virus transmission, infection, and disease: A cross-disciplinary review","volume":"14","author":"Harley","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"2025102309245236500_bib128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.ento.47.091201.145100","article-title":"Ross River virus: Ecology and distribution","volume":"47","author":"Russell","year":"2002","journal-title":"Annu. Rev. Entomol."},{"key":"2025102309245236500_bib129","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3390\/pathogens10030357","article-title":"Ross River virus infection: A cross-disciplinary review with a veterinary perspective","volume":"10","author":"Yuen","year":"2021","journal-title":"Pathogens"},{"key":"2025102309245236500_bib130","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbi.2019.07.034","article-title":"Contribution of individual psychological and psychosocial factors to symptom severity and time-to-recovery after naturally-occurring acute infective illness: The Dubbo Infection Outcomes Study (DIOS)","volume":"82","author":"Cvejic","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"2025102309245236500_bib131","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250001","article-title":"Human immunity","volume":"1","author":"Casanova","year":"2025","journal-title":"J. Hum. Immun."},{"key":"2025102309245236500_bib132","doi-asserted-by":"publisher","first-page":"2250164","DOI":"10.1002\/eji.202250164","article-title":"Autoantibodies targeting type I interferons: Prevalence, mechanisms of induction, and association with viral disease susceptibility","volume":"53","author":"Hale","year":"2023","journal-title":"Eur. J. Immunol."},{"key":"2025102309245236500_bib133","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240365","article-title":"Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies","volume":"221","author":"Fernbach","year":"2024","journal-title":"J. Exp. Med."},{"key":"2025102309245236500_bib134","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/imr.13304","article-title":"Human autoantibodies neutralizing type I IFNs: From 1981 to 2023","volume":"322","author":"Bastard","year":"2024","journal-title":"Immunol. Rev."},{"key":"2025102309245236500_bib135","doi-asserted-by":"publisher","first-page":"1327784","DOI":"10.3389\/fimmu.2024.1327784","article-title":"Interferon autoantibodies as signals of a sick thymus","volume":"15","author":"Oftedal","year":"2024","journal-title":"Front. Immunol."},{"key":"2025102309245236500_bib136","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41586-023-06717-x","article-title":"Autoantibodies against type I IFNs in humans with alternative NF-\u03baB pathway deficiency","volume":"623","author":"Le Voyer","year":"2023","journal-title":"Nature"},{"key":"2025102309245236500_bib137","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2402983121","article-title":"A sensitive assay for measuring whole-blood responses to type I IFNs","volume":"121","author":"Gervais","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025102309245236500_bib138","doi-asserted-by":"publisher","DOI":"10.1101\/2024.06.18.599537","article-title":"Highly-sensitive reporter cell line for detection of interferon types I-III and their neutralization by antibodies","author":"Groen","year":"2024","journal-title":"bioRxiv"},{"key":"2025102309245236500_bib139","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s10875-023-01451-5","article-title":"Anti-GM-CSF neutralizing autoantibodies in Colombian patients with disseminated cryptococcosis","volume":"43","author":"Arango-Franco","year":"2023","journal-title":"J. Clin. Immunol."},{"key":"2025102309245236500_bib140","doi-asserted-by":"publisher","first-page":"ofx211","DOI":"10.1093\/ofid\/ofx211","article-title":"Autoantibodies to granulocyte-macrophage colony-stimulating factor associated with severe and unusual manifestations of cryptococcus gattii infections","volume":"4","author":"Crum-Cianflone","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"2025102309245236500_bib141","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s10875-020-00796-5","article-title":"Anti-GM-CSF autoantibodies and cryptococcus neoformans var. grubii CNS vasculitis","volume":"40","author":"Perrineau","year":"2020","journal-title":"J. Clin. Immunol."},{"key":"2025102309245236500_bib142","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.4049\/jimmunol.1202526","article-title":"Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis","volume":"190","author":"Rosen","year":"2013","journal-title":"J. Immunol."}],"container-title":["Journal of Human Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jhi\/article-pdf\/doi\/10.70962\/jhi.20250090\/1952042\/jhi_20250090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jhi\/article-pdf\/doi\/10.70962\/jhi.20250090\/1952042\/jhi_20250090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:25:04Z","timestamp":1761225904000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jhi\/article\/2\/1\/e20250090\/278393\/Auto-Abs-against-type-I-IFNs-Strong-common-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":142,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,5]]}},"URL":"https:\/\/doi.org\/10.70962\/jhi.20250090","relation":{},"ISSN":["3065-8993"],"issn-type":[{"value":"3065-8993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"article-number":"e20250090"}}